Table 1.
Patient demographics and clinical characteristics stratified by disease state
| Total | Missing data | Non‐worsening disease | Worsening disease | P‐value | |
|---|---|---|---|---|---|
| N = 4,043 | N = 2,315 | N = 1,728 | |||
| Shielded | 2,224 (55.1%) | 9 (0.2%) | 1,240 (53.8%) | 984 (56.9%) | 0.045 |
| Advised to shield | 742 (33.6%) | 1,833 (45.3%) | 465 (37.5%) | 277 (28.6%) | <0.001 |
| Female gender | 2,684 (66.5%) | 5 (0.1%) | 1,362 (59.0%) | 1,322 (76.5%) | <0.001 |
| Age, mean (SD) | 47.2 (15.1) | 31 (0.8%) | 49.5 (15.3) | 44.2 (14.3) | <0.001 |
| White European ethnicity | 3,016 (74.6%) | 0 | 1,707 (73.7%) | 1,309 (75.8%) | 0.15 |
| BMI, mean (SD) | 27.6 (6.0) | 369 (9.1%) | 27.4 (5.8) | 28.0 (6.3) | 0.003 |
| Alcohol >14 units a week | 495 (13.8%) | 455 (11.3%) | 295 (15.0%) | 200 (12.3%) | 0.018 |
| Current smoker | 559 (15.8%) | 498 (12.3%) | 291 (15.0%) | 268 (16.7%) | 0.18 |
| Full time employed | 1,929 (47.7%) | 0 | 1,072 (46.3%) | 857 (49.6%) | 0.038 |
| Household number, mean (SD) | 2.8 (1.8) | 26 (0.6%) | 2.8 (1.7) | 2.9 (1.9) | 0.003 |
| Key worker | 1,131 (28.1%) | 22 (0.5%) | 595 (25.9%) | 536 (31.1%) | <0.001 |
| Psoriasis severity prior to COVID‐19 pandemic | 284 (7%) | <0.001 | |||
| Clear | 451 (12.0%) | 299 (14.6%) | 152 (8.9%) | ||
| Nearly clear | 767 (20.4%) | 463 (22.7%) | 304 (17.7%) | ||
| Mild | 989 (26.3%) | 477 (23.3%) | 512 (29.9%) | ||
| Moderate | 892 (23.7%) | 442 (21.6%) | 450 (26.2%) | ||
| Moderate‐severe | 480 (12.8%) | 273 (13.4%) | 207 (12.1%) | ||
| Severe | 180 (4.8%) | 90 (4.4%) | 90 (5.2%) | ||
| Systemic therapy | 522 (12.9%) | <0.001 | |||
| No systemic therapy | 1,980 (56.2%) | 938 (49.4%) | 1,042 (64.2%) | ||
| Standard systemic therapy | 560 (15.9%) | 309 (16.3%) | 251 (15.5%) | ||
| Targeted therapy | 981 (27.9%) | 652 (34.3%) | 329 (20.3%) | ||
| Non adherent to systemic therapy | 284 (18.4%) | 2507 (62%) | 114 (11.9%) | 170 (29.6%) | <0.001 |
| 1 or more comorbidity | 1,606 (39.7%) | 0 | 908 (39.2%) | 698 (40.4%) | 0.45 |
| Anxiety | 1,069 (30.1%) | 489 (12.1%) | 408 (21.0%) | 661 (41.0%) | <0.001 |
| Depression | 977 (27.5%) | 494 (12.2%) | 392 (20.1%) | 585 (36.5%) | <0.001 |
| Anxiety or depression | 1,376 (38.5%) | 468 (11.6%) | 562 (28.8%) | 814 (50.2%) | <0.001 |
Targeted therapy was defined as anyone taking TNF inhibitors (adalimumab, certolizumab, etanercept, infliximab), IL‐17 inhibitors (ixekizumab, secukinumab, brodalumab), IL‐23 inhibitors (guselkumab, risankizumab, ustekinumab; apremilast). Standard systemic therapy was defined as anyone taking acitretin, ciclosporin, or methotrexate and not taking a targeted therapy.
BMI, body mass index; SD, standard deviation.